Guideline vulvovaginal candidosis (2010) of the german society for gynecology and obstetrics, the working group for infections and infectimmunology in gynecology and obstetrics, the german society of dermatology, the board of german dermatologists and the german speaking mycological society

Candida (C.) species colonize the estrogenized vagina in at least 20% of all women. This statistic rises to 30% in late pregnancy and in immunosuppressed patients. The most often occurring species is Candida albicans.

[1]  R. Schneider,et al.  Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis. , 2010, Medical mycology.

[2]  G. Reid,et al.  Effect of Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14 on the ability of Candida albicans to infect cells and induce inflammation , 2009, Microbiology and immunology.

[3]  K. Friese,et al.  Relationship between recurrent vulvovaginal candidosis and immune mediators in vaginal fluid. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[4]  N. Lowe,et al.  Accuracy of the Clinical Diagnosis of Vaginitis Compared With a DNA Probe Laboratory Standard , 2009, Obstetrics and gynecology.

[5]  J. van Eldere,et al.  Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). , 2008, American journal of obstetrics and gynecology.

[6]  F. Bai,et al.  Biased genotype distributions of Candida albicans strains associated with vulvovaginal candidosis and candidal balanoposthitis in China. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  R. Rawson,et al.  An emerging problem: methamphetamine abuse among treatment seeking youth. , 2008, Substance abuse.

[8]  G. Bellen,et al.  Mannose‐binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis , 2008, BJOG : an international journal of obstetrics and gynaecology.

[9]  K. Schwartz,et al.  Effect of Antibiotics on Vulvovaginal Candidiasis: A MetroNet Study , 2008, The Journal of the American Board of Family Medicine.

[10]  T. Leet,et al.  Self-reported yeast symptoms compared with clinical wet mount analysis and vaginal yeast culture in a specialty clinic setting. , 2008, The Journal of reproductive medicine.

[11]  R. Peralta,et al.  Can intrauterine contraceptive devices be a Candida albicans reservoir? , 2008, Contraception.

[12]  F. D’Antonio,et al.  Two Cases of Vaginitis Caused by Itraconazole-Resistant Saccharomyces cerevisiae and a Review of Recently Published Studies , 2008, Mycopathologia.

[13]  M. Raška,et al.  Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. , 2008, Medical mycology.

[14]  M. Falagas,et al.  Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials. , 2008, American journal of obstetrics and gynecology.

[15]  A. Czeizel,et al.  The use of data set of the Hungarian case-control surveillance of congenital abnormalities for evaluation of birth outcomes beyond birth defects. , 2007, Central European journal of public health.

[16]  J. Grimshaw,et al.  Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). , 2007, The Cochrane database of systematic reviews.

[17]  W. Mendling,et al.  Die vaginale Kolonisation durch Candidaarten unter besonderer Berücksichtigung von Candida dubliniensis , 2007 .

[18]  H. Calabretto,et al.  Comprehensive review of conventional and non‐conventional methods of management of recurrent vulvovaginal candidiasis , 2007, The Australian & New Zealand journal of obstetrics & gynaecology.

[19]  A. Czeizel,et al.  Asymptomatic trichomonas and candida colonization and pregnancy outcome. , 2007, Best practice & research. Clinical obstetrics & gynaecology.

[20]  P. Abrams,et al.  Evidence--based medicine overview of the main steps for developing and grading guideline recommendations. , 2007, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[21]  A. Schwiertz,et al.  Candida autovaccination in the treatment of vulvovaginal Candida infections , 2007, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[22]  M. Cetin,et al.  Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods , 2007, Scandinavian journal of infectious diseases.

[23]  W. Weger,et al.  A 5‐year (2000–2004) epidemiological survey of Candida and non‐Candida yeast species causing vulvovaginal candidiasis in Graz, Austria , 2006, Mycoses.

[24]  S. Garland,et al.  Genital Candida Species Detected in Samples from Women in Melbourne, Australia, before and after Treatment with Antibiotics , 2006, Journal of Clinical Microbiology.

[25]  M. Falagas,et al.  Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. , 2006, The Journal of antimicrobial chemotherapy.

[26]  W. Mendling,et al.  Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy , 2006, Mycoses.

[27]  R. Prasad,et al.  The glyoxylate cycle enzyme activities in the pathogenic isolates of Candida albicans obtained from HIV/AIDS, diabetic and burn patients , 2006, Mycoses.

[28]  R. Goswami,et al.  Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. , 2006, The Journal of infection.

[29]  J. Stockman.  Prospective Randomised Controlled Trial of an Infection Screening Programme to Reduce the Rate of Preterm Delivery , 2006 .

[30]  M. Fisher,et al.  Candida albicans: the estrogen target for vaginal colonization. , 2005, The Journal of surgical research.

[31]  M. Hronek,et al.  The serum levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidosis during attack, remission and in healthy controls , 2005, Mycoses.

[32]  R. Kutner,et al.  Immunotherapeutic approaches to enhance protective immunity against Candida vaginitis. , 2005, Medical mycology.

[33]  Á. Cruz,et al.  Association between atopy and recurrent vaginal candidiasis , 2005, Clinical and experimental immunology.

[34]  D. Kornfeld,et al.  Signs of chronic stress in women with recurrent candida vulvovaginitis. , 2005, American journal of obstetrics and gynecology.

[35]  A. J. Phillips.  Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories. , 2005, American journal of obstetrics and gynecology.

[36]  G. Dennerstein.  Vaginal yeast colonization in nonpregnant women: a longitudinal study. , 2005, Obstetrics and gynecology.

[37]  A. Cassone,et al.  An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis. , 2005, Current molecular medicine.

[38]  W. Ledger,et al.  Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  C. Romano,et al.  Nine male cases of tinea genitalis , 2005, Mycoses.

[40]  Sandra S. Richter,et al.  Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases , 2005, Journal of Clinical Microbiology.

[41]  P. Fidel.  Immunity in vaginal candidiasis , 2005, Current opinion in infectious diseases.

[42]  P. Nyirjesy,et al.  Vaginal Candida parapsilosis: pathogen or bystander? , 2005, Infectious diseases in obstetrics and gynecology.

[43]  A. Cassone,et al.  The Role of Humoral Immunity against Vaginal Candida Infection , 2005 .

[44]  A. Czeizel,et al.  Preterm birth reduction after clotrimazole treatment during pregnancy. , 2004, European journal of obstetrics, gynecology, and reproductive biology.

[45]  B. Hube,et al.  Candida albicans proteinases and host/pathogen interactions , 2004, Cellular microbiology.

[46]  S. Garland,et al.  Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial , 2004, BMJ : British Medical Journal.

[47]  J. Sobel,et al.  Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. , 2004, The New England journal of medicine.

[48]  H. Kiss,et al.  Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery , 2004, British medical journal.

[49]  W. Ip,et al.  Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. , 2004, The Journal of infectious diseases.

[50]  W. Mendling,et al.  A clinical multicenter study comparing efficacy and tolerability of topical combination therapy with clotrimazole (Canesten®, two formats) with oral single dose fluconazole (Diflucan®) in vulvovaginal mycoses , 2004, Mycoses.

[51]  Matthew R. Anderson,et al.  Evaluation of vaginal complaints. , 2004, JAMA.

[52]  C. Bond,et al.  The development of evidence‐ based guidelines for over‐ the‐ counter treatment of vulvovaginal candidiasis , 2003, Pharmacy World and Science.

[53]  D. M. Lupan,et al.  Utilization of siderophores by Candida albicans , 1986, Mycopathologia.

[54]  W. Voigt,et al.  Das Verhalten von Sproßpilzen am nicht verhornenden Plattenepithel , 1974, Archiv für Gynäkologie.

[55]  J. Horrocks,et al.  Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis. , 2003, Journal of women's health.

[56]  S. Corsello,et al.  An epidemiological survey of vulvovaginal candidiasis in Italy. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[57]  P. Chondros,et al.  “Not thrush again!” Women's experience of post‐antibiotic vulvovaginitis , 2003, The Medical journal of Australia.

[58]  M. Schaller,et al.  Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors , 2003, Antimicrobial Agents and Chemotherapy.

[59]  C. Gerlinger,et al.  A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. , 2003, Contraception.

[60]  Heather S Jeavons.  Prevention and treatment of vulvovaginal candidiasis using exogenous Lactobacillus. , 2003, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.

[61]  P. Nyirjesy,et al.  Fluconazole Susceptibility of Vaginal Isolates Obtained from Women with Complicated Candida Vaginitis: Clinical Implications , 2003, Antimicrobial Agents and Chemotherapy.

[62]  J. Sobel,et al.  Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  G. Verbeke,et al.  Impaired tolerance for glucose in women with recurrent vaginal candidiasis. , 2002, American journal of obstetrics and gynecology.

[64]  G. Peterson.  Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. , 2002, Obstetrics and gynecology.

[65]  David Soper,et al.  Over‐the‐Counter Antifungal Drug Misuse Associated With Patient‐Diagnosed Vulvovaginal Candidiasis , 2002, Obstetrics and gynecology.

[66]  P. Stone,et al.  What is a systemic review? , 2002, Applied nursing research : ANR.

[67]  J. Sobel,et al.  Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes , 2002, BMC infectious diseases.

[68]  Jeremy M Grimshaw,et al.  Oral versus intra‐vaginal imidazole and triazole anti‐fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review , 2002, BJOG : an international journal of obstetrics and gynaecology.

[69]  D. Jewell,et al.  Topical treatment for vaginal candidiasis (thrush) in pregnancy. , 2001, The Cochrane database of systematic reviews.

[70]  L. Riley,et al.  Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  D. Ellis,et al.  Oestrogen, glycogen and vaginal candidiasis , 2001, The Australian & New Zealand journal of obstetrics & gynaecology.

[72]  G. Donders.  We, specialists in vulvovaginitis. , 2001, American journal of obstetrics and gynecology.

[73]  J. Grimshaw,et al.  Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). , 2001, The Cochrane database of systematic reviews.

[74]  E. Evans,et al.  Vaginal yeasts in the era of “over the counter” antifungals , 2000, Sexually transmitted infections.

[75]  E. Taketomi,et al.  Candida albicans allergen immunotherapy in recurrent vaginal candidiasis. , 2000, Journal of investigational allergology & clinical immunology.

[76]  R. Goswami,et al.  Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. , 2000, The Journal of infection.

[77]  D. Upmalis,et al.  Single-dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis: two single-blind, controlled studies versus miconazole nitrate 100 mg cream for 7 days. , 2000, Journal of Womens Health & Gender-Based Medicine.

[78]  C. Quéreux,et al.  [Evaluation of the efficacity and speed of action of sertaconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis]. , 2000, Gynecologie, obstetrique & fertilite.

[79]  W. Ledger,et al.  Difficulties in the Diagnosis of Candida Vaginitis , 2000 .

[80]  M. Ghannoum.  Potential role of phospholipases in virulence and fungal pathogenesis. , 2000, Clinical microbiology reviews.

[81]  A. Czeizel,et al.  No teratogenic effect after clotrimazole therapy during pregnancy. , 1999, Epidemiology.

[82]  S. Witkin,et al.  Vaginal heat shock protein expression in symptom-free women with a history of recurrent vulvovaginitis. , 1999, American journal of obstetrics and gynecology.

[83]  J. Sobel,et al.  Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison toC. albicans , 1999, Clinical Microbiology Reviews.

[84]  K. Holmes,et al.  Vulvovaginal Candidiasis: Clinical Manifestations, Risk Factors, Management Algorithm , 1998, Obstetrics and gynecology.

[85]  W. Mendling,et al.  Vergleich der Stammspezifität von Hefepilzen verschiedener Lokalisation bei Frauen mit Vaginalcandidosen , 1998 .

[86]  H. Tietz.  Kommentar zum vorstehenden Beitrag von J. D. Sobel , 1998 .

[87]  R. Blaschke‐Hellmessen.  Subpartale Übertragung von Candida und ihre Konsequenzen , 1998 .

[88]  J. Sobel.  Key Note Lecture Review article Vulvovaginitis due to Candida glabrata. An emerging problem , 1998, Mycoses.

[89]  N. Bohannon.  Treatment of Vulvovaginal Candidiasis in Patients With Diabetes , 1998, Diabetes Care.

[90]  J. Sobel,et al.  Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. , 1997, The Journal of infectious diseases.

[91]  W. Sterry,et al.  Voraussetzungen für eine effektive Therapie chronisch rezidivierender Vaginalcandidosen , 1996 .

[92]  W. Mendling,et al.  Investigations by Cell-Mediated Immunologic Tests and Therapeutic Trials With Thymopentin in Vaginal Mycoses , 1996, Infectious diseases in obstetrics and gynecology.

[93]  P. Nyirjesy,et al.  Chronic fungal vaginitis: the value of cultures. , 1995, American journal of obstetrics and gynecology.

[94]  J. Sobel,et al.  Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[95]  I. Fong,et al.  The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. , 1992, Genitourinary medicine.

[96]  E Hilton,et al.  Ingestion of Yogurt Containing Lactobacillus acidophilus as Prophylaxis for Candidal Vaginitis , 1992, Annals of Internal Medicine.

[97]  T J Walsh,et al.  Nomenclature of fungal diseases: a report and recommendations from a Sub-Committee of the International Society for Human and Animal Mycology (ISHAM). , 1992, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[98]  R. Golz,et al.  Candidosis of the prostate: a rare form of endomycosis , 1991, Mycoses.

[99]  I. Milsom,et al.  Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. , 1990, Genitourinary medicine.

[100]  A. Cassone,et al.  Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. , 1990, The Journal of infectious diseases.

[101]  M. Ghannoum,et al.  Pathogenicity determinants of Candida , 1990, Mycoses.

[102]  B. Foxman.  The epidemiology of vulvovaginal candidiasis: risk factors. , 1990, American journal of public health.

[103]  M. Miller,et al.  Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. , 1990, American journal of obstetrics and gynecology.

[104]  S. Witkin,et al.  A localized vaginal allergic response in women with recurrent vaginitis. , 1988, The Journal of allergy and clinical immunology.

[105]  Dr. Werner Mendling.  Vulvovaginal Candidosis , 1988, Springer Berlin Heidelberg.

[106]  C. S. Chin,et al.  Torulopsis glabrata in vaginitis. , 1988, The Medical journal of Malaysia.

[107]  A. Cassone,et al.  Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. , 1987, The Journal of infectious diseases.

[108]  M. Goldacre,et al.  The pill does not cause ‘thrush’ , 1986, British journal of obstetrics and gynaecology.

[109]  J. Sobel,et al.  Recurrent vulvovaginal candidiasis: vaginal epithelial cell susceptibility to Candida albicans adherence. , 1986, Obstetrics and gynecology.

[110]  J. Cutsem,et al.  Co‐treatment of the male partner in vaginal candidosis: a double‐blind randomized control study , 1986, British journal of obstetrics and gynaecology.

[111]  L. Cohen.  Is more than one application of an antifungal necessary in the treatment of acute vaginal candidiasis? , 1985, American journal of obstetrics and gynecology.

[112]  Tooley Pj.  Patient and doctor preferences in the treatment of vaginal candidosis. , 1985 .

[113]  J. Sobel.  Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. , 1985, Obstetrics and gynecology.

[114]  P. Tooley.  Patient and doctor preferences in the treatment of vaginal candidosis. , 1985, The Practitioner.

[115]  D. Drutz,et al.  Identification of a17β-estradiol binding protein inCandida albicans andCandida (Torulopsis) glabrata , 1984 .

[116]  W. Mendling.  [Torulopsis in gynecology]. , 1984, Geburtshilfe und Frauenheilkunde.

[117]  W. Loeffler.  Terminology of human mycoses. Nomenclature of mycotic diseases of man. List of accepted German terms translated, arranged and published, together with comments, for the International Society for Human and Animal Mycology (ISHAM). , 2009, Mykosen.

[118]  T. Ryder,et al.  Scanning electron microscope study of Candida albicans invasion of cultured human cervical epithelial cells. , 1983, Sabouraudia.

[119]  M. Trost,et al.  A comparison of secretory proteinases from different strains of Candida albicans. , 1982, Sabouraudia.

[120]  E. S. Christensen,et al.  Treatment of Vaginal Candidosis with Natamycin and Effect of Treating the partner at the same time , 1982, Acta obstetricia et gynecologica Scandinavica.

[121]  J. D. Schnell.  Epidemiology and the prevention of peripartal mycoses. , 1982, Chemotherapy.

[122]  M. Wajnberg,et al.  Doppelblind‐Vergleichsstudie mit Ciclopiroxolamin‐ und Miconazol‐Vaginalcreme bei uilvovaginaler Candidose , 1981 .

[123]  N. D. Scheklakow,et al.  Veränderungen der Ultrastruktur von Candida albicans unter der Einwirkung von Polyenantibiotika: Ultrastructural Changes in Candida Albicans caused by Polyene Antibiotics , 1981 .

[124]  J. Sobel,et al.  Adherence of Candida albicans to human vaginal and buccal epithelial cells. , 1981, The Journal of infectious diseases.

[125]  J. Joly,et al.  Microbial flora associated with Candida albicans vulvovaginitis. , 1980, Obstetrics and gynecology.

[126]  M. Plempel.  Pharmakokinetik der Imidazol‐Antimykotika * ) , 1980 .

[127]  N. Rosedale,et al.  Hyposensitisation in the management of recurring vaginal candidiasis. , 1979, Annals of allergy.

[128]  R. Mould,et al.  Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment , 1978, The British journal of venereal diseases.

[129]  W. Meinhof.  Die Salzsaure‐Toleranz von Candida albicans , 1974 .

[130]  R. Blaschke‐Hellmessen.  Epidemiologische Untersuchungen zum Vorkommen von Hefepilzen bei Kindern und deren Müttern * , 1968 .